Dr. Mato on Immunotherapy Options in CLL

Anthony R. Mato, MD, MSCE
Published: Monday, Oct 21, 2019



Anthony R. Mato, MD, MSCE, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia (CLL). 
 
Allogeneic stem cell transplantation is one type of immunotherapy that has shown benefit in CLL, says Mato. CD20-targeted monoclonal antibodies are also immune agonists that are approved in CLL, Mato explains. 
 
Additional immunotherapy strategies are still investigational. Though, CAR T-cell therapy, immune checkpoint inhibitors, and bispecific antibodies are beginning to emerge, says Mato. Mato believes these options will continue to gain traction in the field given their potential to provide long-term disease control.
SELECTED
LANGUAGE


Anthony R. Mato, MD, MSCE, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia (CLL). 
 
Allogeneic stem cell transplantation is one type of immunotherapy that has shown benefit in CLL, says Mato. CD20-targeted monoclonal antibodies are also immune agonists that are approved in CLL, Mato explains. 
 
Additional immunotherapy strategies are still investigational. Though, CAR T-cell therapy, immune checkpoint inhibitors, and bispecific antibodies are beginning to emerge, says Mato. Mato believes these options will continue to gain traction in the field given their potential to provide long-term disease control.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x